Randomised vehicle-controlled dose-finding study of glycosylated recombinant human granulocyte colony-stimulating factor after bone marrow transplantation.
AuthorsLinch, D C
Scarffe, J Howard
Taylor, P R
Morgenstern, Godfrey R
Burnett, A K
Cawley, J C
Franklin, I M
AffiliationUniversity College Hospital, London, UK.
MetadataShow full item record
AbstractA multicentre, randomised vehicle-controlled single-blind dose ranging trial of intravenous recombinant granulocyte colony-stimulating factor (rhuG-CSF) administration after BMT has been performed in 121 patients with non-myeloid malignancies. All the doses of rhuG-CSF used (2-20 micrograms/kg/day) resulted in significant acceleration of neutrophil recovery, and a dose-response effect was apparent (p < 0.05). At the 20 micrograms/kg/day dose of rhuG-CSF the median time taken to achieve a neutrophil count of > 0.5 x 10(9)/1 was reduced from 19 to 13 days (p < 0.001) and the time to achieve a neutrophil count > 1.0 x 10(9)/1 on the first of 3 consecutive days, from 26 to 14 days (p < 0.001). There was a trend to less antibiotic use in the rhuG-CSF recipients and the median time in hospital was markedly reduced by 11-15 days (p < 0.01). There was no toxicity in this study attributable to rhuG-CSF.
CitationRandomised vehicle-controlled dose-finding study of glycosylated recombinant human granulocyte colony-stimulating factor after bone marrow transplantation. 1993, 11 (4):307-11 Bone Marrow Transplant.
JournalBone Marrow Transplantation
- Use of recombinant human granulocyte colony-stimulating factor in children given allogeneic bone marrow transplantation for acute or chronic leukemia.
- Authors: Locatelli F, Pession A, Zecca M, Bonetti F, Prete L, Carrà AM, Prete A, Montagna D, Comoli P, Taibi RM, Paolucci G
- Issue date: 1996 Jan
- Phase II study of glycosylated recombinant human granulocyte colony-stimulating factor after HLA-identical sibling bone marrow transplantation.
- Authors: Lickliter JD, Roberts AW, Grigg AP
- Issue date: 1994 Oct
- Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation.
- Authors: Schmitz N, Dreger P, Zander AR, Ehninger G, Wandt H, Fauser AA, Kolb HJ, Zumsprekel A, Martin A, Hecht T
- Issue date: 1995 Feb
- Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
- Authors: Lemoli RM, Fortuna A, Fogli M, Gherlinzoni F, Rosti G, Catani L, Gozzetti A, Miggiano MC, Tura S
- Issue date: 1995 Dec